CL2021002769A1 - Anticuerpos de unión a vista (divisional solicitud n° 201902610) - Google Patents
Anticuerpos de unión a vista (divisional solicitud n° 201902610)Info
- Publication number
- CL2021002769A1 CL2021002769A1 CL2021002769A CL2021002769A CL2021002769A1 CL 2021002769 A1 CL2021002769 A1 CL 2021002769A1 CL 2021002769 A CL2021002769 A CL 2021002769A CL 2021002769 A CL2021002769 A CL 2021002769A CL 2021002769 A1 CL2021002769 A1 CL 2021002769A1
- Authority
- CL
- Chile
- Prior art keywords
- sight
- divisional application
- binding antibodies
- antibodies
- acidic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La presente solicitud se relaciona con anticuerpos que se unen específicamente al supresor de la activación de células T que contiene el dominio V de inmunoglobulina d(VISTA) a pH ácido y su uso en el tratamiento del cáncer. En algunas modalidades, los anticuerpos se unen específicamente a VISTA humano a pH ácido, pero no se unen significativamente a VISTA humano a pH neutro o fisiológico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762471196P | 2017-03-14 | 2017-03-14 | |
US201862636746P | 2018-02-28 | 2018-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021002769A1 true CL2021002769A1 (es) | 2022-08-12 |
Family
ID=63522565
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019002610A CL2019002610A1 (es) | 2017-03-14 | 2019-09-12 | Anticuerpos de unión a vista a ph ácido. |
CL2021002769A CL2021002769A1 (es) | 2017-03-14 | 2021-10-21 | Anticuerpos de unión a vista (divisional solicitud n° 201902610) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019002610A CL2019002610A1 (es) | 2017-03-14 | 2019-09-12 | Anticuerpos de unión a vista a ph ácido. |
Country Status (16)
Country | Link |
---|---|
US (2) | US11603406B2 (es) |
EP (1) | EP3595720A4 (es) |
JP (2) | JP7211961B2 (es) |
KR (1) | KR20190128198A (es) |
CN (1) | CN110740749A (es) |
AU (1) | AU2018236218A1 (es) |
BR (1) | BR112019019108A2 (es) |
CA (1) | CA3054067A1 (es) |
CL (2) | CL2019002610A1 (es) |
CO (1) | CO2019010943A2 (es) |
IL (1) | IL269240A (es) |
MY (1) | MY200609A (es) |
PE (1) | PE20191708A1 (es) |
SG (1) | SG11201907848YA (es) |
TW (1) | TWI825010B (es) |
WO (1) | WO2018169993A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2568436T3 (es) | 2006-03-31 | 2016-04-29 | Chugai Seiyaku Kabushiki Kaisha | Procedimiento para controlar la farmacocinética en sangre de anticuerpos |
EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
EP4238993A3 (en) | 2008-04-11 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
SG190727A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
KR102147548B1 (ko) | 2011-02-25 | 2020-08-24 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
EP3517550A1 (en) | 2011-11-30 | 2019-07-31 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
TWI697501B (zh) | 2012-08-24 | 2020-07-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
US20160067337A1 (en) * | 2013-03-14 | 2016-03-10 | Bristol-Myers Squibb Company | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
WO2014163101A1 (ja) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Fc領域改変体 |
SG11201607165YA (en) | 2014-12-19 | 2016-09-29 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
TWI808330B (zh) | 2014-12-19 | 2023-07-11 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法 |
TW202248212A (zh) | 2015-02-05 | 2022-12-16 | 日商中外製藥股份有限公司 | 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途 |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8 |
KR102630011B1 (ko) | 2017-01-11 | 2024-01-26 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
JP7211961B2 (ja) | 2017-03-14 | 2023-01-24 | ファイヴ プライム セラピューティクス インク | 酸性pHでVISTAに結合する抗体 |
WO2018217976A1 (en) | 2017-05-25 | 2018-11-29 | Bristol-Myers Squibb Company | Antagonistic cd40 monoclonal antibodies and uses thereof |
AU2019239747A1 (en) * | 2018-03-21 | 2020-10-08 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
US20190300610A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
GB201814562D0 (en) | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
WO2020014327A2 (en) * | 2018-07-11 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
AU2019306165A1 (en) * | 2018-07-20 | 2021-02-25 | Pierre Fabre Medicament | Receptor for vista |
AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
EP4031575A1 (en) * | 2019-09-19 | 2022-07-27 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
WO2023001987A2 (en) | 2021-07-22 | 2023-01-26 | University Of Dundee | Therapeutic muteins |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997913A (en) | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
US5605821A (en) | 1989-03-08 | 1997-02-25 | Board Of Regents Of The University Of Oklahoma | Expression control sequences of the P-selectin gene |
WO1992001718A2 (en) | 1990-07-17 | 1992-02-06 | Board Of Regents Of The University Of Oklahoma | Functionally active selectin-derived peptides and ligand for gmp-140 |
US6277975B1 (en) | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
ATE256182T1 (de) | 1992-10-23 | 2003-12-15 | Inst Genetics Llc | Neuartiges p- selectin ligandenprotein |
US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
AU681369B2 (en) | 1992-11-16 | 1997-08-28 | Board Of Regents Of The University Of Oklahoma, The | Glycoprotein ligand for P-selectin and methods of use thereof |
AU2361395A (en) | 1994-04-28 | 1995-11-29 | Genetics Institute Inc. | Novel P-selectin ligand protein |
EP0850243B1 (en) | 1995-08-03 | 2003-10-08 | Board Of Regents Of The University Of Oklahoma | o-glycan inhibitors of selectin mediated inflammation |
DE69620898T2 (de) | 1995-09-01 | 2002-11-07 | Univ Washington Seattle | Interaktive molekulare konjugate |
CA2315295A1 (en) | 1997-12-18 | 1999-06-24 | Human Genome Sciences, Inc. | 110 human secreted proteins |
EP1090118A2 (en) | 1998-06-26 | 2001-04-11 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
NZ531664A (en) | 1998-09-01 | 2005-07-29 | Genentech Inc | Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family |
AU2883700A (en) | 1999-06-23 | 2001-01-09 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU5249700A (en) | 1999-07-08 | 2001-01-30 | Protegene Inc. | Human proteins having hydrophobic domains and dnas encoding these proteins |
EP1274839A2 (en) | 2000-03-24 | 2003-01-15 | Genetics Institute, LLC | A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor |
US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
US20060141456A1 (en) | 2002-06-12 | 2006-06-29 | Cynthia Edwards | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
AU2003258714A1 (en) | 2002-09-06 | 2004-03-29 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
MY148646A (en) | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
CN105777867A (zh) | 2004-05-11 | 2016-07-20 | 艾比吉诺米克斯合作公司 | 诱导t细胞死亡的表位 |
PT1781682E (pt) | 2004-06-24 | 2013-05-14 | Mayo Foundation | B7-h5, um polipéptido coestimulante |
US8236304B2 (en) | 2005-04-25 | 2012-08-07 | Trustees Of Dartmouth College | Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity |
WO2007033959A2 (en) | 2005-09-19 | 2007-03-29 | Vib Vzw | Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas |
WO2007067984A2 (en) | 2005-12-09 | 2007-06-14 | Wyeth | Neutralizing antibodies against primate psgl-1 and uses therefor |
US7655778B2 (en) | 2006-02-28 | 2010-02-02 | Curonix Co., Ltd. | SISP-1, a novel p53 target gene and use thereof |
ATE536369T1 (de) * | 2006-10-11 | 2011-12-15 | Ablynx Nv | Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung |
WO2009140623A2 (en) | 2008-05-15 | 2009-11-19 | Selexys Pharmaceuticals Corporation | Anti-psgl-1 antibodies and methods of identification and use |
US20120100140A1 (en) | 2009-01-23 | 2012-04-26 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
ES2661310T3 (es) | 2009-03-09 | 2018-03-28 | Bioatla, Llc | Proteínas mirac |
EP2552947A4 (en) | 2010-03-26 | 2013-11-13 | Dartmouth College | VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING ACTIVE SUBSTANCES AND USE THEREOF |
JP6121904B2 (ja) | 2010-09-08 | 2017-04-26 | ハロザイム インコーポレイテッド | 条件的活性治療用タンパク質を評価および同定する、または発展させる方法 |
JP6180408B2 (ja) | 2011-06-13 | 2017-08-16 | アブゲノミクス コーペラティフ ユー.エー. | 抗psgl−1抗体およびその使用 |
EP2771359B1 (en) * | 2011-10-28 | 2021-05-19 | Biogen International Neuroscience GmbH | Tdp-43 specific binding molecules |
CA2857019C (en) | 2011-11-28 | 2022-08-16 | Gray D. Shaw | Soluble tandem selectin glycoprotein ligand molecules |
EA201400993A1 (ru) | 2012-03-08 | 2015-05-29 | Галозим, Инк. | Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения |
US9890215B2 (en) * | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
AU2013277051B2 (en) | 2012-06-22 | 2018-06-07 | King's College London | Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
AU2013312211B2 (en) | 2012-09-07 | 2018-03-29 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
JP6682426B2 (ja) | 2013-05-24 | 2020-04-15 | メディミューン,エルエルシー | 抗b7−h5抗体およびその使用 |
EP3003390B1 (en) | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
WO2015097536A2 (en) * | 2013-12-24 | 2015-07-02 | Janssen Pharmaceutical Nv | Anti-vista antibodies and fragments |
EP3094346B1 (en) | 2014-01-14 | 2019-12-11 | The Trustees Of Dartmouth College | Vista antagonist and methods of use |
CA2949947A1 (en) | 2014-06-04 | 2015-12-10 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for targeting a pathway |
AU2015274504B2 (en) | 2014-06-11 | 2021-02-04 | Kathy A. Green | Use of VISTA agonists and antagonists to suppress or enhance humoral immunity |
CA2953706A1 (en) | 2014-07-08 | 2016-01-14 | Sanford-Burnham Medical Research Institute | Psgl-1 modulators and uses thereof |
JOP20150008B1 (ar) * | 2014-11-26 | 2021-08-17 | Janssen Pharmaceutica Nv | أجسام مضادة ل vista وأجزاء منها |
AU2015357463B2 (en) | 2014-12-05 | 2021-10-07 | Immunext, Inc. | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators |
US10766959B2 (en) | 2014-12-11 | 2020-09-08 | Pierre Fabre Medicament | Anti-C10ORF54 antibodies and uses thereof |
MY188049A (en) * | 2015-05-29 | 2021-11-12 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
BR112017027870A2 (pt) | 2015-06-24 | 2018-08-28 | Janssen Pharmaceutica Nv | anticorpos e fragmentos anti-vista |
US11472876B2 (en) | 2015-11-02 | 2022-10-18 | Bioatla, Inc. | Conditionally active polypeptides |
EP3400239B1 (en) | 2016-01-08 | 2021-06-02 | AltruBio Inc. | Tetravalent anti-psgl-1 antibodies and uses thereof |
US10899836B2 (en) * | 2016-02-12 | 2021-01-26 | Janssen Pharmaceutica Nv | Method of identifying anti-VISTA antibodies |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
WO2017181109A1 (en) | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
CA3020848A1 (en) | 2016-04-15 | 2017-10-19 | Janssen Pharmaceuticals, Inc. | Anti-human vista antibodies and use thereof |
EP3494141A4 (en) | 2016-08-03 | 2020-04-08 | Bio-Techne Corporation | IDENTIFICATION OF VSIG3 / VISTA AS A NEW IMMUNE CONTROL POINT AND ITS USE IN IMMUNOTHERAPY |
WO2018047143A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
KR102630011B1 (ko) | 2017-01-11 | 2024-01-26 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
JP7211961B2 (ja) | 2017-03-14 | 2023-01-24 | ファイヴ プライム セラピューティクス インク | 酸性pHでVISTAに結合する抗体 |
EP3642231A4 (en) | 2017-06-22 | 2021-06-23 | Apexigen, Inc. | ANTI-VISTA ANTIBODIES AND METHODS OF USE |
KR102281405B1 (ko) | 2017-10-20 | 2021-07-26 | 주식회사 파멥신 | 항-vista 항체 및 이의 용도 |
EP3706798A1 (en) | 2017-11-06 | 2020-09-16 | Aurigene Discovery Technologies Limited | Conjoint therapies for immunomodulation |
US20210085785A1 (en) | 2018-02-23 | 2021-03-25 | Truebinding, Inc. | Treating cancer by blocking the interaction of vista and its binding partner |
AU2019239747A1 (en) * | 2018-03-21 | 2020-10-08 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
WO2019185163A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Vista antigen-binding molecules |
US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
WO2020014327A2 (en) | 2018-07-11 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
CN109878421B (zh) | 2019-03-13 | 2020-11-03 | 浙江吉利控股集团有限公司 | 车辆坡道装置及汽车 |
CN110563843A (zh) | 2019-07-25 | 2019-12-13 | 钟小泉 | 一种靶向人vista蛋白的单克隆抗体 |
-
2018
- 2018-03-13 JP JP2019549389A patent/JP7211961B2/ja active Active
- 2018-03-13 KR KR1020197029923A patent/KR20190128198A/ko not_active Application Discontinuation
- 2018-03-13 BR BR112019019108A patent/BR112019019108A2/pt unknown
- 2018-03-13 CN CN201880031212.2A patent/CN110740749A/zh active Pending
- 2018-03-13 AU AU2018236218A patent/AU2018236218A1/en active Pending
- 2018-03-13 WO PCT/US2018/022230 patent/WO2018169993A1/en unknown
- 2018-03-13 SG SG11201907848YA patent/SG11201907848YA/en unknown
- 2018-03-13 CA CA3054067A patent/CA3054067A1/en active Pending
- 2018-03-13 MY MYPI2019004903A patent/MY200609A/en unknown
- 2018-03-13 PE PE2019001859A patent/PE20191708A1/es unknown
- 2018-03-13 US US16/493,712 patent/US11603406B2/en active Active
- 2018-03-13 EP EP18767615.0A patent/EP3595720A4/en active Pending
- 2018-03-14 TW TW107108715A patent/TWI825010B/zh active
-
2019
- 2019-09-10 IL IL26924019A patent/IL269240A/en unknown
- 2019-09-12 CL CL2019002610A patent/CL2019002610A1/es unknown
- 2019-10-02 CO CONC2019/0010943A patent/CO2019010943A2/es unknown
-
2021
- 2021-10-21 CL CL2021002769A patent/CL2021002769A1/es unknown
-
2023
- 2023-01-12 JP JP2023002879A patent/JP2023061927A/ja active Pending
- 2023-02-01 US US18/162,991 patent/US20240092907A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2019002610A1 (es) | 2019-11-29 |
AU2018236218A1 (en) | 2019-09-12 |
US20200055936A1 (en) | 2020-02-20 |
US20240092907A1 (en) | 2024-03-21 |
TWI825010B (zh) | 2023-12-11 |
TW201843171A (zh) | 2018-12-16 |
EP3595720A4 (en) | 2021-05-26 |
CA3054067A1 (en) | 2018-09-20 |
BR112019019108A2 (pt) | 2020-04-22 |
JP2023061927A (ja) | 2023-05-02 |
IL269240A (en) | 2019-11-28 |
US11603406B2 (en) | 2023-03-14 |
KR20190128198A (ko) | 2019-11-15 |
JP2020509756A (ja) | 2020-04-02 |
SG11201907848YA (en) | 2019-09-27 |
MY200609A (en) | 2024-01-05 |
WO2018169993A1 (en) | 2018-09-20 |
CN110740749A (zh) | 2020-01-31 |
CO2019010943A2 (es) | 2020-01-17 |
PE20191708A1 (es) | 2019-11-28 |
JP7211961B2 (ja) | 2023-01-24 |
EP3595720A1 (en) | 2020-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021002769A1 (es) | Anticuerpos de unión a vista (divisional solicitud n° 201902610) | |
CO2020012415A2 (es) | Anticuerpos de unión a vista a ph ácido | |
CL2023002543A1 (es) | Anticuerpos de unión a vista a ph ácido | |
CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
CL2019003266A1 (es) | Anticuerpos anti-sirpalfa. | |
CL2021000039A1 (es) | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas (divisional solicitud 201903796) | |
ECSP18005520A (es) | Anticuerpos de factor xi y métodos de uso | |
ECSP20082648A (es) | Anticuerpos anti-sirpa y métodos de utilización de los mismos | |
BR112018073574A2 (pt) | conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização | |
CL2021000258A1 (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
CO2022014820A2 (es) | Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del síndrome respiratorio agudo grave (sars-cov-2) | |
CL2021003039A1 (es) | Moléculas de unión a tigit y pd-1/tigit | |
AR112102A1 (es) | Tinostamustina para utilizar en el tratamiento de cáncer de ovario | |
UY36261A (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
CO2022002937A2 (es) | Anticuerpos de unión a vista a ph ácido | |
AR120024A1 (es) | ANTICUERPOS DE UNIÓN A VISTA A pH ÁCIDO | |
CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
AR115729A1 (es) | ANTICUERPOS DE UNIÓN A VISTA EN pH ÁCIDO | |
AR115001A1 (es) | ANTICUERPOS DE UNIÓN A VISTA A pH ÁCIDO | |
AR111180A1 (es) | ANTICUERPOS DE UNIÓN A VISTA A pH ÁCIDO | |
CL2022002288A1 (es) | Anticuerpos de unión a vista a ph ácido (divisional solicitud 202002410) | |
AR111715A1 (es) | ANTICUERPOS ANTI-SIRPa | |
EA202092208A1 (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОТНОМ pH |